Pharmalot Ed Silverman STAT Plus: Pharmalittle: We’re reading about Vertex suing HHS over a fertility program, Hawaii losing a PBM suit, and more
Exclusive Mohana Ravindranath STAT Plus: A cancer care startup is making a new bet with payers and providers: only pay if it works
Health Care Inc. Bob Herman STAT Plus: Medicare pay proposals are good news for health tech, bad news for docs
Pharmalot Ed Silverman STAT Plus: Pharmalittle: We’re reading about Senate aides meeting with Novo Nordisk, private drug prices in Germany, and more
Biotech Jason Mast STAT Plus: Early data from Lexeo’s gene therapy for rare heart disease shows promise
Exclusive Nicholas Florko STAT Plus: Top FDA officials weighing regulation of ultra-processed foods, internal documents show
Pharmalot Ed Silverman STAT Plus: Pharmalittle: We’re reading about a study of Ozempic and dementia, smaller PBMs, and more
In the Lab Rohan Rajeev STAT Plus: The biggest misconception about CTE, according to a leading brain trauma expert
Health tech Mario Aguilar STAT Plus: Medicare proposes to cover some digital therapies in a breakthrough for health tech firms
Pharmalot Ed Silverman STAT Plus: Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more
Pharma Matthew Herper and Elaine Chen STAT Plus: Pfizer says it will advance once-daily GLP-1 pill after all
Adam's Take Adam Feuerstein STAT Plus: Roche’s TIGIT study was a bust. What’s the outlook for its next big bet?
Pharmalot Ed Silverman STAT Plus: FTC plans to sue PBMs over the high cost of insulin and other medicines
Politics Bob Herman STAT Plus: Biden administration ignores calls to bolster hospital price transparency
Hospitals Tara Bannow STAT Plus: Sanford Health aims to shake off a run of failed deals by snapping up a $3 billion Wisconsin health system
Health Isabella Cueto Researchers identify ‘molecular switch’ in lupus that could stymie harmful immune response
Pharmalot Ed Silverman STAT Plus: Pharmalittle: We’re reading about biopharma layoffs, Purdue bankruptcy talks, and more
Biotech Jonathan Wosen STAT Plus: Biopharma layoffs are leaving the industry’s scientists reeling — and in search of scarce opportunities
D.C. Diagnosis Sarah Owermohle STAT Plus: The pharmaceutical industry keeps losing Washington friends
Biotech Matthew Herper STAT Plus: Mikael Dolsten, Pfizer CSO who could take on Covid but not Wall Street, to step down
Pharmalot Ed Silverman STAT Plus: Pharmalittle: We’re reading about an FTC report on PBMs, Lilly vs. Novo weight loss study, and more
Pharmalot Ed Silverman STAT Plus: FTC report finds PBMs profit at the expense of patients and independent pharmacies
Opinions+ Bruce Leuchter STAT Plus: Private equity and neuroscience: a novel approach to developing new treatments for neurological disorders
Biotech Jason Mast STAT Plus: A faster, simpler, cheaper cancer cell therapy is about to be tested in humans
Pharmalot Ed Silverman STAT Plus: South Africa and J&J reach a deal to widen access to a key tuberculosis treatment